The aim of this study is to explore the effects of hormone replacement therapy with EV/DNG on abdominal fat distribution measured by magnetic resonance imaging.
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
67
1 tablet daily (2 mg EV + 2 mg DNG)
1 tablet daily
Unnamed facility
Vienna, Vienna, Austria
Unnamed facility
Vienna, Austria
Unnamed facility
Vienna, Austria
Individual relative change of abdominal visceral fat measured by magnetic resonance imaging
Time frame: Baseline and after 24 weeks of treatment
Parameters of body composition and lipid metabolism
Time frame: Baseline and after 24 weeks of treatment
Adverse events collection
Time frame: During whole study period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.